Abstract
Atopic dermatitis (AD) skin lesions are associated with oozing, bleeding, and erythema that are primarily driven by polarized type 2 immune responses. These suggest vascular changes in AD. Dupilumab is an antibody to the alpha-subunit of interleukin (IL)-4 receptor that demonstrates robust efficacy in the treatment of moderate-to-severe AD. IL-4 is known to reduce the permeability barrier function of vascular endothelium. The effect of dupilumab on vascular barrier function in AD is unknown.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
